Polypharmacy and Activities of Daily Living in Older Patients Undergoing Cerebrovascular Rehabilitation: An Observational Study Using Japanese Real-World Data - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Polypharmacy and Functional Independence in Older Adults Receiving Cerebrovascular Rehabilitation: An Observational Study of Japanese Real-World Data

  • By

  • Yukari Ogawa

  • Takeshi Horii

  • Masaharu Sakoh

  • Kiyoshi Mihara

  • October 12, 2026

Share

Objective:

To examine the association between polypharmacy status during hospitalization and functional outcomes among older adults receiving convalescent rehabilitation for cerebrovascular disease.

Approach:
  • Design and data: Retrospective observational study using anonymized inpatient and pharmacy claims data from the Japan Medical Data Center database, covering April 2014 to January 2025.
  • Participants: Patients aged 65 years or older admitted for the first time to a convalescent rehabilitation ward for cerebrovascular rehabilitation were included, subject to the study’s exclusion criteria.
  • Exposure and outcomes: Polypharmacy was defined as use of at least six medications. Patients were classified according to polypharmacy status at admission and discharge: persistent non-polypharmacy, polypharmacy at admission only, polypharmacy at discharge only, or polypharmacy at both admission and discharge. Outcomes were FIM gain, FIM efficiency, and length of stay.
Key Findings:
  • Polypharmacy was common among older patients receiving convalescent rehabilitation for cerebrovascular disease.
  • FIM gain did not differ significantly by polypharmacy-status group.
  • Compared with the persistent non-polypharmacy group, each of the other three groups had lower FIM efficiency and longer hospital stays.
Interpretation:

In this observational study, polypharmacy-status groups differed in FIM efficiency and length of stay, but not significantly in FIM gain. These associations do not show that polypharmacy caused the differences.

Limitations:
  • The retrospective observational design cannot establish causation.
  • The information available here does not provide the sample size, effect estimates, confidence intervals, or full statistical analysis; the magnitude and precision of the reported differences therefore cannot be assessed.
Conclusion:

Polypharmacy status during hospitalization was associated with lower FIM efficiency and longer hospital stays, but not with significant differences in FIM gain. Further research is needed to clarify these associations.

Sources:

Original Source(s)

Related Content